Literaturnachweis - Detailanzeige
| Autor/inn/en | Greenhill, Laurence L.; Biederman, Joseph; Boellner, Samuel W.; Rugino, Thomas A.; Sangal, R. Bart; Earl, Craig Q.; Jiang, John G.; Swanson, James M. |
|---|---|
| Titel | A Randomized, Double-Blind, Placebo-Controlled Study of Modafinil Film-Coated Tablets in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder |
| Quelle | In: Journal of the American Academy of Child and Adolescent Psychiatry, 45 (2006) 5, S.503-511 (9 Seiten)
PDF als Volltext |
| Sprache | englisch |
| Dokumenttyp | gedruckt; online; Zeitschriftenaufsatz |
| ISSN | 0890-8567 |
| Schlagwörter | Patients; Adolescents; Hyperactivity; Attention Deficit Disorders; Drug Therapy; Outcomes of Treatment; Comparative Analysis; Symptoms (Individual Disorders); Sleep |
| Abstract | Objective: To evaluate the efficacy and tolerability of modafinil in children and adolescents, ages 7 to 17, with attention-deficit/hyperactivity disorder (ADHD). Method: In this 9-week, double-blind, flexible-dose study, patients were randomized to once-daily modafinil (170-425 mg) or placebo. Assessments included ADHD Rating Scale-IV (ADHD-RS-IV) School and Home Versions and Clinical Global Impression of Improvement (CGI-I) scale. Results: Two hundred patients were randomized. Modafinil produced significant reductions in ADHD-RS-IV total scores at school (n = 128; mean change plus or minus SD: -17.5 plus or minus 13.1 points) compared with placebo (n = 66; -9.7 plus or minus 10.3 points; p less than 0.0001). Similarly, modafinil reduced ADHD-RS-IV total scores at home compared with placebo (-17.6 plus or minus 13.3 versus -7.5 plus or minus 11.8 points; p less than 0.0001). Fifty-two percent of patients randomized to modafinil and 18% of those randomized to placebo met prestudy criteria for responder on the CGI-I (p less than 0.0001). Randomization to modafinil was associated with significantly more insomnia, headache, decreased appetite, and weight loss than randomization to placebo, but discontinuation attributed to adverse events did not differ statistically between treatment groups (modafinil, 5%; placebo, 6%). Conclusion: Modafinil was well tolerated and reduced ADHD symptoms at school and home compared with placebo. (Contains 3 figures and 4 tables.) (Author). |
| Anmerkungen | Lippincott Williams & Wilkins. P.O. Box 1600, Hagerstown, MD 21741. Tel: 800-638-3030; Tel: 301-223-2300; Fax: 301-223-2400; Web site: http://www.lww.com/product/?0890-8567 |
| Erfasst von | ERIC (Education Resources Information Center), Washington, DC |
| Update | 2017/4/10 |
Literaturbeschaffung und Bestandsnachweise in Bibliotheken prüfen
Permalink als QR-Code
Inhalt auf sozialen Plattformen teilen (nur vorhanden, wenn Javascript eingeschaltet ist)
Teile diese Seite:
